These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 22023666)

  • 41. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors.
    Taylor J; Baldo OB; Storey A; Cartledge J; Eardley I
    BJU Int; 2009 May; 103(10):1392-5. PubMed ID: 19154494
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
    Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
    Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [PDE5 inhibitors in treatment of benign prostatic syndrome].
    Sandner P; Tinel H; Stelte-Ludwig B; Huetter J; Neuser D; Bischoff E; Ulbrich E
    Urologe A; 2007 Sep; 46(9):1189-92. PubMed ID: 17609921
    [No Abstract]   [Full Text] [Related]  

  • 44. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
    Rubio-Aurioles E; Porst H; Kim ED; Montorsi F; Hackett G; Morales AM; Stuckey B; Būttner H; West TM; Huynh NN; Lenero E; Burns P; Kopernicky V
    J Sex Med; 2012 May; 9(5):1418-29. PubMed ID: 22429760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.
    Fusco F; Sicuteri R; Rossi A; Kontodimas S; Haro JM; Imbimbo C; Mirone V;
    Asian J Androl; 2009 Sep; 11(5):629-37. PubMed ID: 19701217
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education.
    Hackett GI
    Clin Cornerstone; 2005; 7(1):57-65. PubMed ID: 16156424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How new drugs help treat erectile dysfunction.
    Weeks B; Ficorelli CT
    Nursing; 2006 Jan; 36(1):18-9. PubMed ID: 16394991
    [No Abstract]   [Full Text] [Related]  

  • 48. There have been inadequate warnings that erectile dysfunction drugs can cause blindness.
    Wolfe SM
    MedGenMed; 2005 Dec; 7(4):61. PubMed ID: 16614683
    [No Abstract]   [Full Text] [Related]  

  • 49. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
    Carson CC
    Am J Cardiol; 2005 Dec; 96(12B):37M-41M. PubMed ID: 16387565
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sildenafil or vardenafil nonresponders' erectile response to tadalafil.
    Ozgur BC; Gonenc F; Yazicioglu AH
    Urol J; 2009; 6(4):267-71. PubMed ID: 20027555
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients.
    Lombardi G; Macchiarella A; Cecconi F; Del Popolo G
    J Sex Med; 2009 May; 6(5):1248-58. PubMed ID: 19210710
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Editorial comment on the manuscript entitled 'Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction'.
    Perimenis P
    Expert Opin Pharmacother; 2005 Jan; 6(1):1-2. PubMed ID: 15709877
    [No Abstract]   [Full Text] [Related]  

  • 53. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
    Vickers MA; Satyanarayana R
    Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors.
    Jannini EA; DeRogatis LR; Chung E; Brock GB
    J Sex Med; 2012 Jan; 9(1):26-33. PubMed ID: 22221307
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of sildenafil and vardenafil on erectile dysfunction and health-related quality of life in haemodialysis patients: a prospective randomized crossover study.
    Turk S; Solak Y; Kan S; Atalay H; Kilinc M; Agca E; Bodur S
    Nephrol Dial Transplant; 2010 Nov; 25(11):3729-33. PubMed ID: 20466680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PDEI-5 for erectile dysfunction: a potential role in seizure susceptibility.
    Matos G; Scorza FA; Cavalheiro EA; Tufik S; Andersen ML
    J Sex Med; 2012 Aug; 9(8):2111-21. PubMed ID: 22613050
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phosphodiesterase type 5 inhibitors: the day after.
    Hatzimouratidis K; Hatzichristou D
    Eur Urol; 2007 Jan; 51(1):75-88; discussion 89. PubMed ID: 16949200
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
    Lui JL; Shaw NM; Abbasi B; Hakam N; Breyer BN
    Andrology; 2023 Oct; 11(7):1408-1417. PubMed ID: 36905319
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors?
    Aliferis K; Petropoulos IK; Farpour B; Matter MA; Safran AB
    Ophthalmologica; 2012; 227(2):85-9. PubMed ID: 22156704
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient education series. Erectile dysfunction.
    Lewis JH; Rosen R; Goldstein I
    Nursing; 2005 Feb; 35(2):64. PubMed ID: 15706284
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.